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Introduction
The use of antimicrobial agents in veterinary medicine is regarded as a serious concern for the emergence of bacterial resistance ( ; ) and the antimicrobial treatments should not only aim at curing the diseased animals Aarestrup and Wegener, 1999 Phillips et al., 2004 but also at limiting the resistance. To preserve individuals in situations at risk, a choice has to be made between two strategies: (i) an early collective treatment, also called control or metaphylaxis, in which all the animals of a group that are actually exposed to a pathogen are treated even if, at the time of treatment, only few animals show symptoms of infection or (ii) a later individual treatment in which only the animals of the group showing clinical symptoms of the disease are treated. The advantages and limitations of these two strategies need to be scientifically documented in a framework of risk-benefit analysis. The first strategy is challenged by the argument that the treatment of all the animals of a group is an overuse of antibiotics which is suspected to favour the emergence of resistant bacteria, especially in the digestive commensal flora. However, these collective treatments are launched very early after the start of the infection and consequently the bacterial load targeted by the antibiotic is supposedly lower than for the second strategy of the late treatment of animals with clinical symptoms. Therefore, the assessment of the impact of the bacterial load on the clinical and microbiological outcomes may be a key factor in making a decision between the two strategies. Indeed, previous studies have shown that the eradication of the targeted bacterial population needed lower concentrations of antibiotic ( ; ; ) and that Mizunaga et al., 2005 Morrissey and George, 1999 Udekwu et al., 2009 the selection of resistant subpopulations of the pathogen was less frequent when a low bacterial inoculum was compared to a high inoculum ( ; ; ). Ferran et al., 2007 Ferran et al., 2009 Kesteman et al., 2009 In the present study, we assessed the impact of early versus late curative administration of marbofloxacin, a fluoroquinolone extensively used in veterinary medicine, on the survival of mice, the eradication of bacteria and the prevention of resistance during the natural course of a lung infection with , a bacterium responsible for pneumonia in cattle and swine.
Pasteurella multocida

Materials and methods
Bacteria and antibiotic
Vet Microbiol . Author manuscript Page / 2 7 A strain of isolated from the trachea of a pig with clinical symptoms of a bacterial lung infection was used as Pasteurella multocida the test bacteria. Marbofloxacin, a third generation fluoroquinolone, was used as the test antibiotic.
In vitro susceptibility testing
MIC determination
The MICs were determined in triplicate according to the CLSI reference methods ( ).
CLSI, 2006
Determination of the Mutant Prevention Concentration (MPC)
The MPC was determined as previously described ( ). Briefly, an overnight culture of the test bacteria in Mueller Blondeau et al., 2001 Hinton broth (MHB) was concentrated 100 times in 0.9 NaCl to obtain a suspension containing 10 CFU/mL. One hundred microliters of 
Lung infection model
Female Swiss mice were anesthetized by an intraperitoneal injection of a mixture of 0.17 mg/kg medetomidine (Domitor , Pfizer, ND France) and 80 mg/kg ketamine (Chlorketam , V toquinol, France). The tracheas were cannulated with a 22 G catheter without mandrel.
ND é
The catheter was inserted through the glottis into the trachea until the connector was behind the incisors. The lungs were inoculated with 20 L of a suspension containing ~5.10 CFU/mL corresponding to a total of ~1000 CFU/lung. Most of the mice μ Pasteurella multocida 4 had dyspnea, lethargy and dehydration 24 to 48 hours after the inoculation of . Eighteen control mice, that were not Pasteurella multocida treated, were used to assess the natural growth of in the lungs. Among these mice, groups of 3 mice each were Pasteurella multocida sacrificed by an intraperitoneal injection of pentobarbital sodium (Dolethal , Vetoquinol, France) 1, 5, 10, 24, 32 and 48 hours after the ND inoculation of bacteria and the susceptible and resistant bacteria were counted in the lungs. The pharmacodynamic assay was carried out with four groups of 14 mice each that received a single marbofloxacin dose of 1 or 40 mg/kg intraperitoneally 10 (early administration) or 32 (late administration) hours after the inoculation of the bacteria. The mice were all sacrificed 38 hours after the marbofloxacin administration. Two other groups of 14 mice that received a single dose of 1 or 40 mg/kg marbofloxacin intraperitoneally 32 hours after the inoculation (late administration) were sacrificed 16 hours after the marbofloxacin administration. There were also 28 control mice that did not receive marbofloxacin and that were sacrificed 48 hours after the inoculation. To count the susceptible and resistant bacteria, the lungs were aseptically removed and homogenized in 10 mL of 0.9 NaCl. The homogenates were centrifuged at 3000 g for 10 minutes % and the pellets were resuspended in 2.5 mL of 0.9 NaCl. Ten microliters of successive 10-fold dilutions of homogenates were then plated % in triplicate on MH drug-free agar plates or on MH plates supplemented with 0.128 g/mL of marbofloxacin corresponding to the first μ dilution step below the MPC. The colonies were counted after 24 hours of incubation at 37 C. If the colonies were too small, incubation°w as continued for a further 24 hours. The lowest level of detection was 100 CFU/lung and bacteria were considered eradicated below this level.
Pharmacokinetics
Female Swiss mice, satellites from the pharmacodynamic assay, were infected with as described above and Pasteurella multocida were given a single intraperitoneal dose of 20 mg/kg marbofloxacin, 10 (early administration) or 32 (late administration) hours later.
Groups of 3 mice each were anesthetized by intraperitoneal injection of pentobarbital sodium (Dolethal , Vetoquinol, France) 0.25, 0.5, ND 1, 2, 4, 6, 8, 12, 18 or 24 hours after dosing. Blood samples (one sample from each animal) were collected by puncture of the caudal vena cava and centrifuged at 7000 g for 10 min at 4 C. The plasma samples were stored at 20 C until assay. A simple and sensitive high°−°p erformance liquid chromatography method, using ultraviolet detection at 295 nm was used to determine marbofloxacin concentrations in the plasma. Briefly, samples were extracted by solid phase extraction on a C8 100 mg cartridge. Marbofloxacin and the internal standard, ofloxacin, were separated on a reverse-phase C18 Inertsil ODS-3 column and eluted with 25 mM citrate buffer (pH 3.0) and acetonitrile in = an 85:15 ratio. The standard calibration curve for marbofloxacin, using a weighted linear regression model, was linear for concentrations ranging from 0.01 to 2 g/mL. The intra-day and inter-day precision ranged from 4.58 to 9.27 and from 4.85 to 9.46 respectively. The 
Results
Susceptibility studies
The MIC and the MPC of marbofloxacin for were 0.016 and 0.256 g/mL respectively. The term resistant Pasteurella multocida μ "
bacteria in the present paper should be understood as bacteria growing in the presence of 0.128 g/mL marbofloxacin, the first dilution " μ step below the MPC.
Pharmacokinetics
The observed (total) and the predicted ( . Assuming dose-proportionality, the AUC and C values were proportional to the dose for Table 1 max a given administration time. For a given dose, the AUC values were much greater (3 -fold) for the mice treated late than for those treated early. The values of C were quite independent of the administration time. 
Growth of in mice Pasteurella multocida
The time-course of bacteria growth in control mouse lungs is shown in . The bacterial population inoculated in the trachea Figure 2 was about 1000 CFU/mouse. One hour after the inoculation, the total bacterial populations were 2.56 0.58 log CFU/lung. Ten hours after time. Thirty-two hours after the inoculation, corresponding to the late marbofloxacin administration time in the subsequent experiments, the bacterial population ranged from 1.10 to 9.10 CFU/lung. Hence, for the late marbofloxacin administrations, the lungs contained 25 6 8 000-fold more bacteria (from 50 to 2.10 -fold) than for the early administrations and the clinical status of mice was worse: they showed 5 anorexia, lethargy and dehydration. Some resistant bacteria were found 48 hours after the inoculation in one lung in a proportion of 6.10 4 − .
Clinical and microbiological outcomes
Clinical outcome: mouse survival
The percentage of mice alive 38 hours after marbofloxacin administration for each dosing regimen (dose and administration time) are reported in . For the control group, 64 (10 died out of 28) of the mice were alive 48 hours after the inoculation. There was no Table 2 % mortality 38 hours after early marbofloxacin administration (i.e. 48 hours after the inoculation) included for the low dose of 1 mg/kg.
Thirty-eight hours after the late administration (i.e. 70 hours after the inoculation), the high dose of 40 mg/kg marbofloxacin, only prevented the death of 10 mice out of 14. Seven mice out of 14 were dead after a late low dose of 1 mg/kg marbofloxacin.
Microbiological outcome: total bacterial populations
The percentage of mice with bacterial eradication 38 hours after marbofloxacin administration and the bacterial counts in mice without eradication are reported in . No bacteria were recovered in two mice of the control group. The early administration of the 40 mg/kg Table 2 marbofloxacin dose (10 hours after the inoculation) was the only dosing regimen able to eradicate the bacteria in all the mice. The same dose of 40 mg/kg marbofloxacin administered late (32 hours after the inoculation), did not eradicate the bacteria in one mouse in addition to the 4 dead mice. The early administration of the 1 mg/kg dose (10 hours after the inoculation), even if it prevented the death of all the mice, did not eradicate the bacteria in 5 mice out of 14. For a given dose, the late administration resulted in a less frequent eradication of bacteria in the lungs than the early administration. Table 3 bacteria in the control group were always less than 1.5.10 whereas the proportions after an exposure to marbofloxacin were always more 3 − than 3.3.10 indicating selective pressure by marbofloxacin. Due to the high mortality of mice ( ) having received the late 2 − Table 2 marbofloxacin administration and the consequent impossibility of assessing if the dead mice carried resistant bacteria or not, we decided to sacrifice two additional groups of mice 16 hours after the late administration of 1 or 40 mg/kg marbofloxacin to count susceptible and resistant bacterial populations before the death of mice. In these additional groups, resistant bacteria were assessed in all the mice except two that had received 1 mg/kg marbofloxacin and were dead at the time of sacrifice. Resistant bacteria were found in 4 lungs and in one after late administration of 1 and 40 mg/kg marbofloxacin respectively. Thus the earlier sacrifice at 16 hours after late marbofloxacin administration enabled more mice carrying resistant bacteria to be identified after the 1 mg/kg dose. The early administration of 1 mg/kg marbofloxacin and the late administration of 40 mg/kg marbofloxacin gave similar outcomes in terms of resistance since only one mouse per group had a high proportion of resistant bacteria. Therefore the dose level alone cannot explain the selection of resistance, which seemed to depend also on the marbofloxacin administration time.
Resistant bacterial populations
4 7 Resistant bacteria were found in 6 infected mice in the non-treated group and in one lung per dosing regimen (dose and administration time) after marbofloxacin administration except for the early 40 mg/kg dose which had eradicated all the bacteria. The percentage of mice carrying resistant bacteria and the proportions of resistant bacteria in these mice are reported in . The proportions of resistant
Discussion
In veterinary medicine, to preserve the health of a herd or a flock, collective antimicrobial treatments can be administered to all the animals after the observation of symptoms in only few animals of the group. This practice is referred to as metaphylaxis which corresponds to the administration of antibiotics to animals experiencing any level of bacterial disease before overt disease ( ). Young, 1995 According to this definition, metaphylaxis is launched after ( ) the start of the infectious disease whose initiating event is the meta disruption of the host defenses associated with a bacterial contamination or an asymptomatic bacteria carriage. In this respect, metaphylaxis should be viewed for the majority of the animals as a curative treatment occurring early in the time scale of the infection, its goal being the bacteriological cure of infected animals, which subsequently warrants the final protection ( ) against infection phylaxis outbreaks. Although these early curative uses before the onset of symptoms of a bacterial infection may be considered as overuse of ; ; Kesteman et al.; ; in vitro in vivo Ferran et al., 2007 Ferran et al., 2009 Jumbe et al., 2003 Mizunaga et al., 2005 ) studies on the influence of inoculum size on the pharmacodynamics of antimicrobial drugs did not take into account Udekwu et al., 2009 the natural course of the bacterial growth. Indeed, the different sizes of inoculum tested were directly inoculated into broth or animals, whereas in this current study, the initial inoculum of inoculated into the tracheas was the same for all the mice and Pasteurella multocida the initiation of marbofloxacin administration was then more or less delayed. At the early marbofloxacin administration time (10 hours after the inoculation), the mice had no clinical symptoms and this early administration could be considered as representative of the early curative use of antimicrobial drugs in the context of metaphylaxis since there was an infection (see control group) but no clinical symptoms, mimicking what is observed in veterinary practice. At the late administration time (32 hours after the inoculation), the mice were anorexic, lethargic and dehydrated and this administration was representative of later conventional curative treatments. As found that the different inoculum sizes associated with the different administration times after bacterial inoculation had a dramatic influence on the bactericidal activity. Indeed, for a given marbofloxacin dose (1 or 40 mg/kg), the clinical outcome (survival of mice) and the eradication of bacteria were improved after early rather than late treatments. The need for a higher marbofloxacin dose to ensure the survival of mice for the late treatment was in agreement with the 20-fold higher, 50 effective dose of ciprofloxacin, for mouse survival study, the early administration of 1 mg/kg marbofloxacin gave a higher survival rate and a similar percentage of bacterial eradication as the late administration of 40 mg/kg marbofloxacin. In the case of resistance selection at the infectious site, for a given dose, the early treatments were always associated with less selection for resistant bacteria than the late treatments. For resistance, as for bacterial eradication, similar percentages were obtained after an early administration of 1 mg/kg and a late administration of 40 mg/kg marbofloxacin.
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To assess whether the differences between outcomes after early and late treatment can be explained by differences in the exposure of bacteria to marbofloxacin, we investigated the marbofloxacin kinetics after early (10 hours after the inoculation) and late administration (32 hours after the inoculation) during the natural course of the infection. The clearance of marbofloxacin in mice receiving 20 mg/kg early after the inoculation of (1250 mL.h .kg ) was in accordance with the clearance in mice infected in the thighs Pasteurella multocida observation highlights the need to do pharmacokinetic studies on infected animals during drug development and also when doing experiments with rodent models in order to accurately determine the internal exposure to the antibiotic. In this study, the antibiotic clearance was three-fold lower (370 mL.h .kg ) in mice given marbofloxacin late during the time course of the infection than in the 1 − 1 − mice with early administration, meaning that for the same dose, the bacteria in late treated mice had an exposure to marbofloxacin three times higher than the bacteria in mice treated early. This difference in marbofloxacin kinetics should have been an advantage for the late treatment over the early treatment for bactericidal activity and prevention of resistance. This was not the case in our experiment indicating that the three-times higher exposure associated with the same dose during the late treatment compared with the early treatment was not sufficient to compensate for the deleterious effects of the disease and/or the inoculum size. The exposure (AUC) had to be 135-fold higher for late treatment (108 g.h.mL obtained with 40 mg/kg administration) than for early treatment (0.8 g.h.mL obtained after 1 mg/kg
to give similar outcomes. In this study, we arbitrarily decided to assess the effects of 1 and 40 mg/kg marbofloxacin and these two doses are most likely not the optimal ones for the early and late treatments of this experimental infection. However, the assessment of two doses with a 40-fold difference enabled us to highlight that the dose may depend on the time of treatment during the course of the infection and that the optimal doses are likely to be lower in the case of early compared with late treatment.
In conclusion, our results support the hypothesis that the same dosage regimen given early during the time-course of a bacterial infection may lead to both more frequent clinical and microbiological cures and to a less frequent selection of resistant bacteria than later treatments. In addition, this study supports the view that different dosage regimens should be established to obtain required clinical and microbiological cures as well as resistance prevention depending on the type of use of an antibiotic, i.e. early or late during the course of the infection. We investigated the selection of resistance at the infection site but not on the digestive commensal flora which is the main argument against early treatments that are criticised for being an overuse of antibiotics. However, as a result of this study, we can initially reply that early lower doses gave the same microbiological and clinical outcomes as late higher doses. Indeed, even if all the animals of a herd are treated in the case of early treatment, the consumption of antibiotic per individual could be lower. By taking this element into account, further studies should now investigate at group level the impact on the overall consumption of antibiotic and on the selection of resistance, of different individual doses given to non-symptomatic animals in early metaphylactic curative treatments compared to " " diseased animals in the later conventional treatments.
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TABLE 2
Percentage of surviving mice, percentage of mice with bacterial eradication and bacterial counts in the lungs without eradication 38 hours after marbofloxacin administration for each dose and each
